• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种针对糖蛋白IIIa构象决定簇的单克隆抗体对纤维蛋白(原)与活化血小板结合的抑制作用。

Inhibition of fibrin(ogen) binding to stimulated platelets by a monoclonal antibody specific for a conformational determinant of GPIIIa.

作者信息

Ramsamooj P, Doellgast G J, Hantgan R R

机构信息

Department of Biochemistry, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina 27103.

出版信息

Thromb Res. 1990 Jun 15;58(6):577-92. doi: 10.1016/0049-3848(90)90304-u.

DOI:10.1016/0049-3848(90)90304-u
PMID:2385828
Abstract

We have purified the integrin GPIIb:IIIa from the membrane fraction of human blood platelets by lentil lectin affinity chromatography followed by gel filtration chromatography. With purified GPIIb:IIIa as an antigen, we have produced monoclonal antibody CS-1, which immunoblotting demonstrates to be specific for native GPIIIa; disulfide bond reduction of GPIIIa resulted in loss of immunoreactivity. Radiolabelled ligand binding studies revealed that CS-1 recognized approximately 55,000 sites per platelet and bound with a Kd in the nanomolar range, independent of the state of platelet activation. Binding of CS-1 or its Fab fragment to ADP- and thrombin-stimulated gel filtered platelets caused a 2-3 fold inhibition of binding the soluble ligands fibrinogen and fibrin protofibrils. CS-1 also inhibited aggregation of ADP- and thrombin-stimulated platelets by 2- and 4-fold, respectively. Since CS-1 inhibits fibrin(ogen) interactions with GPIIb:IIIa, we propose that the conformationally dependent epitope on GPIIIa recognized by CS-1 constitutes a region of the receptor which is involved in fibrin(ogen) binding.

摘要

我们通过扁豆凝集素亲和层析,随后进行凝胶过滤层析,从人血小板的膜组分中纯化了整合素GPIIb:IIIa。以纯化的GPIIb:IIIa作为抗原,我们制备了单克隆抗体CS-1,免疫印迹显示其对天然GPIIIa具有特异性;GPIIIa的二硫键还原导致免疫反应性丧失。放射性标记配体结合研究表明,CS-1识别每个血小板约55,000个位点,结合常数在纳摩尔范围内,且与血小板激活状态无关。CS-1或其Fab片段与ADP和凝血酶刺激的凝胶过滤血小板结合,导致可溶性配体纤维蛋白原和纤维蛋白原纤维的结合受到2至3倍的抑制。CS-1还分别使ADP和凝血酶刺激的血小板聚集受到2倍和4倍的抑制。由于CS-1抑制纤维蛋白(原)与GPIIb:IIIa的相互作用,我们提出CS-1识别的GPIIIa上构象依赖性表位构成了受体中参与纤维蛋白(原)结合的区域。

相似文献

1
Inhibition of fibrin(ogen) binding to stimulated platelets by a monoclonal antibody specific for a conformational determinant of GPIIIa.一种针对糖蛋白IIIa构象决定簇的单克隆抗体对纤维蛋白(原)与活化血小板结合的抑制作用。
Thromb Res. 1990 Jun 15;58(6):577-92. doi: 10.1016/0049-3848(90)90304-u.
2
Fibrin protofibril and fibrinogen binding to ADP-stimulated platelets: evidence for a common mechanism.纤维蛋白原纤维和纤维蛋白原与ADP刺激的血小板结合:共同机制的证据。
Biochim Biophys Acta. 1988 Jan 18;968(1):24-35. doi: 10.1016/0167-4889(88)90040-7.
3
Heterogenous inhibition of platelet aggregation by monoclonal antibodies binding to multiple sites on GPIIIa.通过与糖蛋白IIIa上多个位点结合的单克隆抗体对血小板聚集的异质性抑制。
Br J Haematol. 1995 Dec;91(4):976-82. doi: 10.1111/j.1365-2141.1995.tb05422.x.
4
Detection of an epitope specific for the dissociated form of glycoprotein IIIa of platelet membrane glycoprotein IIb-IIIa complex and its expression on the surface of adherent platelets.血小板膜糖蛋白IIb-IIIa复合物解离形式的糖蛋白IIIa特异性表位的检测及其在黏附血小板表面的表达。
Br J Haematol. 1993 Oct;85(2):332-40. doi: 10.1111/j.1365-2141.1993.tb03175.x.
5
[Conformational changes of the platelet membrane glycoprotein IIb-IIIa complex stimulated by a monoclonal antibody to the N-terminal segment of glycoprotein IIIa].[抗糖蛋白IIIa N端片段单克隆抗体刺激下血小板膜糖蛋白IIb-IIIa复合物的构象变化]
Biokhimiia. 1996 Mar;61(3):412-28.
6
Aggregation of chymotrypsin-treated thrombasthenic platelets is mediated by fibrinogen binding to glycoproteins IIb and IIIa.经胰凝乳蛋白酶处理的血小板无力症血小板的聚集是由纤维蛋白原与糖蛋白IIb和IIIa结合介导的。
J Lab Clin Med. 1985 Dec;106(6):651-60.
7
Factor XIIIa binding to activated platelets is mediated through activation of glycoprotein IIb-IIIa.凝血因子 XIIIa 与活化血小板的结合是通过糖蛋白 IIb-IIIa 的活化介导的。
Blood. 1994 Feb 15;83(4):1006-16.
8
Complement proteins C5b-9 initiate secretion of platelet storage granules without increased binding of fibrinogen or von Willebrand factor to newly expressed cell surface GPIIb-IIIa.补体蛋白C5b-9启动血小板储存颗粒的分泌,而不会增加纤维蛋白原或血管性血友病因子与新表达的细胞表面糖蛋白IIb-IIIa的结合。
J Biol Chem. 1988 Aug 25;263(24):11907-14.
9
A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex.一种新的鼠单克隆抗体显示血小板糖蛋白IIb/IIIa复合物的构象和/或微环境存在激活依赖性变化。
J Clin Invest. 1985 Jul;76(1):101-8. doi: 10.1172/JCI111931.
10
Differences between platelet and microparticle glycoprotein IIb/IIIa.血小板与微粒糖蛋白IIb/IIIa之间的差异。
Cytometry. 1992;13(6):621-9. doi: 10.1002/cyto.990130610.

引用本文的文献

1
An αIIbβ3 monoclonal antibody traps a semiextended conformation and allosterically inhibits large ligand binding.一种 αIIbβ3 单克隆抗体捕获半延伸构象并变构抑制大配体结合。
Blood Adv. 2024 Aug 27;8(16):4398-4409. doi: 10.1182/bloodadvances.2024013177.
2
Binding of a fibrinogen mimetic stabilizes integrin alphaIIbbeta3's open conformation.一种纤维蛋白原模拟物的结合可稳定整合素αIIbβ3的开放构象。
Protein Sci. 2001 Aug;10(8):1614-26. doi: 10.1110/ps.3001.
3
Time and force dependence of the rupture of glycoprotein IIb-IIIa-fibrinogen bonds between latex spheres.
乳胶球之间糖蛋白IIb-IIIa-纤维蛋白原键断裂的时间和力依赖性
Biophys J. 2000 Mar;78(3):1195-206. doi: 10.1016/S0006-3495(00)76677-X.
4
Glanzmann thrombasthenia resulting from a single amino acid substitution between the second and third calcium-binding domains of GPIIb. Role of the GPIIb amino terminus in integrin subunit association.由糖蛋白IIb(GPIIb)第二和第三钙结合结构域之间的单个氨基酸取代导致的Glanzmann血小板无力症。GPIIb氨基末端在整合素亚基缔合中的作用。
J Clin Invest. 1995 Apr;95(4):1553-60. doi: 10.1172/JCI117828.
5
Modeling the alpha IIb beta 3 integrin solution conformation.模拟αIIbβ3整合素的溶液构象。
Protein Sci. 1993 Dec;2(12):2154-66. doi: 10.1002/pro.5560021215.
6
Evidence that the central region of glycoprotein IIIa participates in integrin receptor function.糖蛋白IIIa的中央区域参与整合素受体功能的证据。
Biochem J. 1991 Jun 15;276 ( Pt 3)(Pt 3):725-32. doi: 10.1042/bj2760725.